However, in December 2004 the United States the 14-member Food and Drug Administration (FDA) advisory committee, plus voting consultants, for Reproductive Health Drugs unanimously rejected Procter and Gamble's fast-track request for Intrinsa citing concerns about off-label use . In Canada, post-menopausal women have been able to obtain government-approved testosterone treatment since 2002. In Australia, post-menopausal women can use Organon testosterone implants which have to be surgically inserted and last from three to six months. 
Short-term side effects include insomnia, high blood pressure, night sweats, increased aggression and libido. However, since women will suffer virilization effects even at small doses, this drug should not be taken by a female. Kidney toxicity has been suggested, but has not yet been proven, and scientific evidence supporting the idea is absent from the bodybuilding community that perpetuates this idea. The origin of this myth most likely has to do with the rust colored oxidized metabolites of trenbolone which are excreted in urine and often mistaken for blood. Trenbolone and 17epi-trenbolone are both excreted in urine as conjugates that can be hydrolyzed with beta-glucuronidase. This implies that trenbolone leaves the body as beta-glucuronides or sulfates.